澳门威尼斯人网站,唯一品牌【官网】

both of which were mild and self-limiting. , who were separated into low-dose, of which 96 participated in phase-1 clinical trials and 224 participated in phase-2 trials. The research reported geometric mean titers of neutralizing antibodies in the volunteers。

reporting that no serious adverse reactions were observed. The most common adverse reaction was pain at the injection site, medium-dose and high-dose groups. The results showed that the vaccine effectively induced neutralizing antibodies in the volunteers and demonstrated good immunogenicity -- the ability of a substance to trigger an immune response. The research paper also evaluated the safety of the vaccine,澳门威尼斯人网址澳门威尼斯人网址, Aug. 16 (Xinhua) -- An inactivated COVID-19 vaccine candidate developed by China is safe and generates an immune response,。

according to data from clinical trials published in The Journal of the American Medical Association this week. The research paper provided an interim analysis of the phase-1 and phase-2 clinical trials of an inactivated COVID-19 vaccine developed by the Wuhan Institute of Biological Products under the China National Biotec Group (CNBG), followed by fever,澳门威尼斯人网站澳门威尼斯人网址澳门威尼斯人官网 澳门威尼斯人网站, and the Wuhan Institute of Virology under the Chinese Academy of Sciences. The research involved data on 320 healthy volunteers aged between 18 and 59。

affiliated to Sinopharm, BEIJING。